Zepbound and Mounjaro have now underperformed expectations for two straight quarters.
Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared.
The pharmaceutical giant also issued fiscal 2025 profit guidance of $22.05 to $23.55 per share, which is in line with what analysts were expecting. Eli Lilly reiterated its fiscal 2025 sales guidance of $58 billion to $61 billion.later this year, a few months earlier than expected. Retatrutide works differently from any of the treatments on the market, mimicking three different hunger-regulating hormones: GLP-1, GIP and glucagon.
Eli Lilly said the increase reflects strong demand and increased supply of Mounjaro, but was partially offset by lower realized prices due to "favorable changes" in the fourth quarter of 2023 to estimates for rebates and discounts.
Breaking News: Business Health Care Industry Pharmaceuticals Biotech And Pharmaceuticals Biotechnology Business Earnings LILLY DRN Novo Nordisk A/S Novo Nordisk A/S Business News
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Medicare Now Covers Eli Lilly's Obesity Drug Zepbound for Sleep ApneaMedicare Part D plans can now cover Eli Lilly's obesity drug Zepbound for patients with obstructive sleep apnea, expanding its accessibility.
Read more »
Medicare to Cover Eli Lilly's Obesity Drug Zepbound for Sleep ApneaMedicare Part D plans can now cover Eli Lilly's obesity drug Zepbound for patients with obstructive sleep apnea (OSA), expanding access to the medication. This coverage decision follows the FDA's recent approval of Zepbound for treating both obesity and moderate-to-severe OSA.
Read more »
Eli Lilly Stock: A Look Beyond the GLP-1 BoomEli Lilly's (LLY) stock performance in 2024 was largely driven by its successful GLP-1 drugs, Mounjaro and Zepbound. However, the company's future prospects extend beyond this booming segment. Eli Lilly is investing in a pill version of tirzepatide, developing promising oncology drugs, and expanding GLP-1 production. Despite recent market dips, Eli Lilly remains well-positioned for continued growth in 2025 and beyond.
Read more »
Eli Lilly Cuts 2024 Revenue Forecast Amid Softer Demand for Weight Loss and Diabetes DrugsEli Lilly, a leading pharmaceutical company, reduced its 2024 revenue outlook due to lower-than-expected sales for its weight loss and diabetes medications. The company now predicts annual revenue of around $45 billion, down from its previous estimate. This downgrade reflects the slower-than-anticipated growth of incretin drugs, a class that includes Mounjaro and Zepbound, which are key products for Eli Lilly.
Read more »
Cramer Sees Long-Term Potential in Healthcare Stocks, Highlights Eli Lilly and Merck as WinnersCNBC's Jim Cramer advocates for long-term investing in healthcare, particularly in pharmaceutical companies like Eli Lilly and Merck. He believes these companies are undervalued by Wall Street despite their strong growth prospects, driven by innovative treatments and a wider range of applications for existing drugs.
Read more »
Eli Lilly Cuts 2024 Revenue Forecast Amid Lower-Than-Expected Demand for Obesity and Diabetes DrugsEli Lilly has downgraded its 2024 revenue projection due to weaker-than-anticipated demand for its weight loss and diabetes medications. The company cites a slowdown in growth and lower-than-expected inventory levels as contributing factors.
Read more »